Maxim Group Thinks Atossa Genetics’ Stock is Going to Recover


Maxim Group analyst Jason McCarthy maintained a Buy rating on Atossa Genetics (ATOS) today and set a price target of $5. The company’s shares closed on Friday at $1.14, close to its 52-week low of $1.12.

McCarthy noted:

“Atossa announced that the FDA has approved ‘expanded access’ to oral Endoxifen for a single patient in the pre-operative setting (neoadjuvent).”

According to TipRanks.com, McCarthy is a 2-star analyst with an average return of 0.3% and a 37.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Atossa Genetics with a $5 average price target.

See today’s analyst top recommended stocks >>

Based on Atossa Genetics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.31 million. In comparison, last year the company had a GAAP net loss of $2.18 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts